Drug
Lisdexamfetamine Dimesylate
Lisdexamfetamine Dimesylate: highest development phase Post-Market, developed by Takeda. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lisdexamfetamine dimesylate NCT01552902 | Post-Market | Attention-deficit/Hyperactivity Disorder |
| Lisdexamfetamine Dimesylate NCT01106430 | Phase 3 | Attention-Deficit/Hyperactivity Disorder |
Latest
No recent events.
Follow Lisdexamfetamine Dimesylate on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.